Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2009

Sanofi-Aventis Licenses Intelliject’s Epinephrine Auto-Injector for $25M Up Front

  • Sanofi-aventis obtained the rights to Intelliject’s epinephrine auto-injector for the emergency treatment of anaphylaxis in the U.S. and Canada. Under the license, sanofi-aventis U.S. will be responsible for manufacturing and commercialization. Intelliject will be responsible for the ongoing development and for obtaining U.S. regulatory approval. Intelliject has retained certain co-promotion rights.

    Sanofi-aventis U.S. will make an initial up-front payment of $25 million. Intelliject will also be eligible to receive development and commercial milestones of up to $205 million as well as tiered double-digit royalties on sales of any products commercialized under the license.

    "This partnership marks a key milestone in our quest to make our novel epinephrine auto-injector available to the millions of patients at risk for anaphylaxis. We expect it to create significant long-term value for the company; it marks the first step on our mission to bring the same innovation and patient-centric solutions to many different therapy areas," says Spencer Williamson, president and CEO of Intelliject.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »